|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
2
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tomimaru Y, Wada H, Eguchi H, Tomokuni A,
Hama N, Kawamoto K, Marubashi S, Umeshita K, Doki Y, Mori M, et al:
Clinical significance of surgical resection of metastatic lymph
nodes from hepatocellular carcinoma. Surg Today. 45:1112–1120.
2015. View Article : Google Scholar
|
|
4
|
Kobayashi T, Ishiyama K and Ohdan H:
Prevention of recurrence after curative treatment for
hepatocellular carcinoma. Surg Today. 43:1347–1354. 2013.
View Article : Google Scholar
|
|
5
|
Valent P, Bonnet D, De Maria R, Lapidot T,
Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi
G, et al: Cancer stem cell definitions and terminology: The devil
is in the details. Nat Rev Cancer. 12:767–775. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bonnet D and Dick JE: Human acute myeloid
leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fang D, Nguyen TK, Leishear K, Finko R,
Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE and Herlyn M: A
tumorigenic subpopulation with stem cell properties in melanomas.
Cancer Res. 65:9328–9337. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
O'Brien CA, Pollett A, Gallinger S and
Dick JE: A human colon cancer cell capable of initiating tumour
growth in immunodeficient mice. Nature. 445:106–110. 2007.
View Article : Google Scholar
|
|
10
|
Ma S, Lee TK, Zheng BJ, Chan KW and Guan
XY: CD133+ HCC cancer stem cells confer chemoresistance
by preferential expression of the Akt/PKB survival pathway.
Oncogene. 27:1749–1758. 2008. View Article : Google Scholar
|
|
11
|
Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai
P, Chu PW, Lam CT, Poon RT and Fan ST: Significance of
CD90+ cancer stem cells in human liver cancer. Cancer
Cell. 13:153–166. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yamashita T, Ji J, Budhu A, Forgues M,
Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, et al:
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating
cells with stem/progenitor cell features. Gastroenterology.
136:1012–1024. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J and
Li J: Cancer stem/progenitor cells are highly enriched in
CD133+CD44+ population in hepatocellular
carcinoma. Int J Cancer. 126:2067–2078. 2010. View Article : Google Scholar
|
|
14
|
Stange T, Kettmann U and Holzhausen HJ:
Immunoelectron microscopic single and double labelling of
aminopeptidase N (CD 13) and dipeptidyl peptidase IV (CD 26). Acta
Histochem. 98:323–331. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dixon J, Kaklamanis L, Turley H, Hickson
ID, Leek RD, Harris AL and Gatter KC: Expression of
aminopeptidase-n (CD 13) in normal tissues and malignant neoplasms
of epithelial and lymphoid origin. J Clin Pathol. 47:43–47. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bhagwat SV, Lahdenranta J, Giordano R,
Arap W, Pasqualini R and Shapiro LH: CD13/APN is activated by
angiogenic signals and is essential for capillary tube formation.
Blood. 97:652–659. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kehlen A, Egbert I, Thiele K, Fischer K,
Riemann D and Langner J: Increased expression of interleukin-8 and
amino-peptidase N by cell-cell contact: Interleukin-8 is resistant
to degradation by aminopeptidase N/CD13. Eur Cytokine Netw.
12:316–324. 2001.PubMed/NCBI
|
|
18
|
Ishii K, Usui S, Sugimura Y, Yoshida S,
Hioki T, Tatematsu M, Yamamoto H and Hirano K: Aminopeptidase N
regulated by zinc in human prostate participates in tumor cell
invasion. Int J Cancer. 92:49–54. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hashida H, Takabayashi A, Kanai M, Adachi
M, Kondo K, Kohno N, Yamaoka Y and Miyake M: Aminopeptidase N is
involved in cell motility and angiogenesis: Its clinical
significance in human colon cancer. Gastroenterology. 122:376–386.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tokuhara T, Hattori N, Ishida H, Hirai T,
Higashiyama M, Kodama K and Miyake M: Clinical significance of
aminopeptidase N in non-small cell lung cancer. Clin Cancer Res.
12:3971–3978. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Haraguchi N, Ishii H, Mimori K, Tanaka F,
Ohkuma M, Kim HM, Akita H, Takiuchi D, Hatano H, Nagano H, et al:
CD13 is a therapeutic target in human liver cancer stem cells. J
Clin Invest. 120:3326–3339. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sekine K, Fujii H and Abe F: Induction of
apoptosis by bestatin (ubenimex) in human leukemic cell lines.
Leukemia. 13:729–734. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ezawa K, Minato K and Dobashi K: Induction
of apoptosis by ubenimex (Bestatin) in human non-small-cell lung
cancer cell lines. Biomed Pharmacother. 50:283–289. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Terauchi M, Kajiyama H, Shibata K, Ino K,
Nawa A, Mizutani S and Kikkawa F: Inhibition of APN/CD13 leads to
suppressed progressive potential in ovarian carcinoma cells. BMC
Cancer. 7:1402007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al; SHARP Investigators Study Group. Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lencioni R, Petruzzi P and Crocetti L:
Chemoembolization of hepatocellular carcinoma. Semin Intervent
Radiol. 30:3–11. 2013. View Article : Google Scholar :
|
|
27
|
Nagano H, Wada H, Kobayashi S, Marubashi
S, Eguchi H, Tanemura M, Tomimaru Y, Osuga K, Umeshita K, Doki Y,
et al: Long-term outcome of combined interferon-α and
5-fluorouracil treatment for advanced hepatocellular carcinoma with
major portal vein thrombosis. Oncology. 80:63–69. 2011. View Article : Google Scholar
|
|
28
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bijnsdorp IV, Giovannetti E and Peters GJ:
Analysis of drug interactions. Methods Mol Biol. 731:421–434. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wickström M, Larsson R, Nygren P, Gullbo J
and Aminopeptidase N: Aminopeptidase N (CD13) as a target for
cancer chemotherapy. Cancer Sci. 102:501–508. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hitzerd SM, Verbrugge SE, Ossenkoppele G,
Jansen G and Peters GJ: Positioning of aminopeptidase inhibitors in
next generation cancer therapy. Amino Acids. 46:793–808. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Naka K, Muraguchi T, Hoshii T and Hirao A:
Regulation of reactive oxygen species and genomic stability in
hematopoietic stem cells. Antioxid Redox Signal. 10:1883–1894.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Maeda S, Wada H, Naito Y, Nagano H,
Simmons S, Kagawa Y, Naito A, Kikuta J, Ishii T, Tomimaru Y, et al:
Interferon-α acts on the S/G2/M phases to induce apoptosis in the
G1 phase of an IFNAR2-expressing hepatocellular carcinoma cell
line. J Biol Chem. 289:23786–23795. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Qin LF and Ng IO: Induction of apoptosis
by cisplatin and its effect on cell cycle-related proteins and cell
cycle changes in hepatoma cells. Cancer Lett. 175:27–38. 2002.
View Article : Google Scholar
|
|
35
|
Fan C, Zheng W, Fu X, Li X, Wong YS and
Chen T: Strategy to enhance the therapeutic effect of doxorubicin
in human hepatocellular carcinoma by selenocystine, a synergistic
agent that regulates the ROS-mediated signaling. Oncotarget.
5:2853–2863. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sawafuji K, Miyakawa Y, Weisberg E,
Griffin JD, Ikeda Y and Kizaki M: Aminopeptidase inhibitors inhibit
proliferation and induce apoptosis of K562 and STI571-resistant
K562 cell lines through the MAPK and GSK-3beta pathways. Leuk
Lymphoma. 44:1987–1996. 2003. View Article : Google Scholar
|
|
37
|
Liang W, Gao B, Xu G, Weng D, Xie M and
Qian Y: Possible contribution of aminopeptidase N (APN/CD13) to
migration and invasion of human osteosarcoma cell lines. Int J
Oncol. 45:2475–2485. 2014.PubMed/NCBI
|
|
38
|
Prasad V, Chandele A, Jagtap JC, Sudheer
Kumar P and Shastry P: ROS-triggered caspase 2 activation and
feedback amplification loop in beta-carotene-induced apoptosis.
Free Radic Biol Med. 41:431–442. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Madesh M, Zong WX, Hawkins BJ, Ramasamy S,
Venkatachalam T, Mukhopadhyay P, Doonan PJ, Irrinki KM, Rajesh M,
Pacher P, et al: Execution of superoxide-induced cell death by the
proapoptotic Bcl-2-related proteins Bid and Bak. Mol Cell Biol.
29:3099–3112. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Balaban RS, Nemoto S and Finkel T:
Mitochondria, oxidants, and aging. Cell. 120:483–495. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chetram MA, Bethea DA, Odero-Marah VA,
Don-Salu-Hewage AS, Jones KJ and Hinton CV: ROS-mediated activation
of AKT induces apoptosis via pVHL in prostate cancer cells. Mol
Cell Biochem. 376:63–71. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
McCubrey JA, Lahair MM and Franklin RA:
Reactive oxygen species-induced activation of the MAP kinase
signaling pathways. Antioxid Redox Signal. 8:1775–1789. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
El-Najjar N, Chatila M, Moukadem H,
Vuorela H, Ocker M, Gandesiri M, Schneider-Stock R and
Gali-Muhtasib H: Reactive oxygen species mediate
thymoquinone-induced apoptosis and activate ERK and JNK signaling.
Apoptosis. 15:183–195. 2010. View Article : Google Scholar
|
|
44
|
Navarro R, Busnadiego I, Ruiz-Larrea MB
and Ruiz-Sanz JI: Superoxide anions are involved in
doxorubicin-induced ERK activation in hepatocyte cultures. Ann NY
Acad Sci. 1090:419–428. 2006. View Article : Google Scholar
|
|
45
|
Massaoka MH, Matsuo AL, Figueiredo CR,
Farias CF, Girola N, Arruda DC, Scutti JA, Romoff P, Favero OA,
Ferreira MJ, et al: Jacaranone induces apoptosis in melanoma cells
via ROS-mediated downregulation of Akt and p38 MAPK activation and
displays antitumor activity in vivo. PLoS One. 7:e386982012.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yu CC, Wu PJ, Hsu JL, Ho YF, Hsu LC, Chang
YJ, Chang HS, Chen IS and Guh JH: Ardisianone, a natural
benzoquinone, efficiently induces apoptosis in human
hormone-refractory prostate cancers through mitochondrial damage
stress and survivin downregulation. Prostate. 73:133–145. 2013.
View Article : Google Scholar
|
|
47
|
Hao W, Yuan X, Yu L, Gao C, Sun X, Wang D
and Zheng Q: Licochalcone A-induced human gastric cancer BGC-823
cells apoptosis by regulating ROSmediated MAPKs and PI3K/AKT
signaling pathways. Sci Rep. 18:52015.
|
|
48
|
Hartmann KU and Heidelberger C: Studies on
fluorinated pyrimidines. XIII. Inhibition of thymidylate
synthetase. J Biol Chem. 236:3006–3013. 1961.PubMed/NCBI
|
|
49
|
Wang D and Lippard SJ: Cellular processing
of platinum anti-cancer drugs. Nat Rev Drug Discov. 4:307–320.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lenaz L, Necco A, Dasdia T and Di Marco A:
Biologic activity of some adriamycin (NSC-123127) derivatives.
Cancer Chemother Rep. 58:769–776. 1974.PubMed/NCBI
|
|
51
|
Wilhelm SM, Carter C, Tang L, Wilkie D,
McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al:
BAY 43-9006 exhibits broad spectrum oral antitumor activity and
targets the RAF/MEK/ERK pathway and receptor tyrosine kinases
involved in tumor progression and angiogenesis. Cancer Res.
64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hashimoto N, Tsunedomi R, Yoshimura K,
Watanabe Y, Hazama S and Oka M: Cancer stem-like sphere cells
induced from de-differentiated hepatocellular carcinoma-derived
cell lines possess the resistance to anti-cancer drugs. BMC Cancer.
14:7222014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wakita A, Ohtake S, Takada S, Yagasaki F,
Komatsu H, Miyazaki Y, Kubo K, Kimura Y, Takeshita A, Adachi Y, et
al: Randomized comparison of fixed-schedule versus
response-oriented individualized induction therapy and use of
ubenimex during and after consolidation therapy for elderly
patients with acute myeloid leukemia: The JALSG GML200 Study. Int J
Hematol. 96:84–93. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ichinose Y, Genka K, Koike T, Kato H,
Watanabe Y, Mori T, Iioka S, Sakuma A and Ohta M; NK421 Lung Cancer
Surgery Group. Randomized double-blind placebo-controlled trial of
bestatin in patients with resected stage I squamous-cell lung
carcinoma. J Natl Cancer Inst. 95:605–610. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Xu JW, Li CG, Huang XE, Li Y and Huo JG:
Ubenimex capsule improves general performance and chemotherapy
related toxicity in advanced gastric cancer cases. Asian Pac J
Cancer Prev. 12:985–987. 2011.PubMed/NCBI
|
